Biotech Archives - Page 86 of 795

1 minute read

Alpine Immune Sciences To Present Updated Clinical Data For Povetacicept In IgA Nephropathy At The World Congress Of Nephrology 2024

April 1, 9:05 AM

-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients ---- The Company will host an investor event the same day concurrently with the poster presentation

ALPN

4 minute read

Biomea Fusion Highlights Initial Data From The First Two Type 1 Diabetes Patients Dosed With BMF-219

By Benzinga Newsdesk

April 1, 9:04 AM

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both

BMEA

2 minute read

Abbott Receives FDA Clearance For Whole Blood Rapid Test To Help With Assessment Of Concussion At The Patient’s Bedside

By Benzinga Newsdesk

April 1, 9:01 AM

The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussionThe test produces lab-quality results

ABT

2 minute read

Viracta Therapeutics To Present Topline Nana-val Results From Stage 1 of the NAVAL-1 Trial At The 2024 Annual Congress Of The Hematology Society Of Taiwan

By Benzinga Newsdesk

April 1, 8:34 AM

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that topline

VIRX

2 minute read

Clinical Collaboration Agreement between Teva And Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Rescue Inhaler Respiratory Program; Teva And Abingworth Enter Strategic Development Funding Agreement To Provide Up To $150M To Offse…

By Benzinga Newsdesk

April 1, 8:33 AM

Collaboration combines Teva's expertise in respiratory technology development and Launch Therapeutics' innovative late-stage drug development model to progress Teva's Dual-Action Asthma Rescue Inhaler (TEV-‘248)

2 minute read

Vistagen Initiates PALISADE-3 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder Following Results Of PALISADE-2

By Benzinga Newsdesk

April 1, 8:31 AM

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety disorder affects over 25 million AmericansVistagen (NASDAQ:VTGN), a late clinical-stage

VTGN

3 minute read

Disc Reports Topline Results From Phase 2 AURORA Study Of Bitopertin In Patients With Erythropoietic Protoporphyria; Met Primary Endpoint, Demonstrating Dose-Dependent, Statistically Significant Reductions In Protoporphyrin IX; Improved Measures Of Lig…

By Benzinga Newsdesk

April 1, 8:13 AM

Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including

IRON

2 minute read

Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome

By Benzinga Newsdesk

April 1, 8:11 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

CORT

2 minute read

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual…

By Benzinga Newsdesk

April 1, 8:09 AM

- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis- Represents the

ATNM

1 minute read

Vincerx To Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented At The American Association For Cancer Research Annual Meeting 2024

By Benzinga Newsdesk

April 1, 8:08 AM

Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing

VINC